Future therapies in hormone-refractory prostate cancer
- 31 May 2005
- Vol. 65 (5) , 9-16
- https://doi.org/10.1016/j.urology.2005.03.043
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal WomenJournal of Bone and Mineral Research, 2004
- Combined Analysis of Two Multicenter, Randomized, Placebo-Controlled Studies of Pamidronate Disodium for the Palliation of Bone Pain in Men With Metastatic Prostate CancerJournal of Clinical Oncology, 2003
- A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastasesProceedings of the National Academy of Sciences, 2003
- Osteoclast differentiation and activationNature, 2003
- A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate CarcinomaJNCI Journal of the National Cancer Institute, 2002
- New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockadeUrology, 1999
- Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostateNature Medicine, 1995
- Analysis of Bone Metastasis of Prostatic Adenocarcinoma in 137 Autopsy CasesPublished by Springer Nature ,1992
- Massive amounts of immunoreactive endothelin in human seminal fluidJournal of Clinical Endocrinology & Metabolism, 1992
- A novel potent vasoconstrictor peptide produced by vascular endothelial cellsNature, 1988